{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:24:40Z","timestamp":1781655880961,"version":"3.54.5"},"reference-count":15,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"1","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":71,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>People with serious mental illness may be subjected to \u201ccourt-ordered treatment\u201d (COT), per the mental health statutes of their respective state. COT enforces adherence to a psychiatric treatment regimen and may involve involuntary medication administration. Long-acting injectable (LAI) antipsychotics are frequently used in this setting, although little is known about the clinical effectiveness or patterns of use of these agents in the context of COT. Because psychiatric pharmacists are medication experts, we sought to characterize their perceptions and experiences on this topic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cross-sectional, electronic, 14-item survey was administered via the College of Psychiatric and Neurologic Pharmacists listserv from October 9, 2018, to November 9, 2018. The survey collected demographic information, experience and use of LAI antipsychotics at each practice site, and perception of LAI antipsychotics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 843 possible respondents, 72 completed the survey, yielding an 8.5% response rate. LAIs were perceived as underused or adequately used as a whole, with a significant difference in perception favoring the opinion that LAIs are underused versus overused for those respondents who perceived an adherence benefit (P\u2009=\u2009.042). We also found that LAIs were used disproportionately in the context of COT versus oral formulations (P\u2009=\u2009.03).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>The use of LAIs in the context of COT has not been studied, and it may expose this vulnerable population to adverse effects from medications they are legally compelled to take. Further research on the perceptions of other interdisciplinary team members and the clinical impact of LAI use in COT is needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2020.01.018","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T19:48:15Z","timestamp":1578599295000},"page":"18-24","source":"Crossref","is-referenced-by-count":7,"title":["Long-acting injectable antipsychotics and their use in court-ordered treatment: A cross-sectional survey of psychiatric pharmacists' perceptions"],"prefix":"10.9740","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4171-4985","authenticated-orcid":false,"given":"Joseph","family":"Cusimano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2294-2694","authenticated-orcid":false,"given":"Amy","family":"VandenBerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"key":"2020060307362733700_i2168-9709-10-1-18-b01","article-title":"Mental illness [Internet]","year":"2017"},{"key":"2020060307362733700_i2168-9709-10-1-18-b02","article-title":"Position statement 22: involuntary mental health treatment [Internet]","year":"2019"},{"key":"2020060307362733700_i2168-9709-10-1-18-b03","article-title":"Position statement on involuntary outpatient commitment and related programs of assisted outpatient treatment [Internet]","year":"2015"},{"issue":"5","key":"2020060307362733700_i2168-9709-10-1-18-b04","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/01.pra.0000388626.98662.a0","article-title":"Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines","volume":"16","author":"Velligan","year":"2010","journal-title":"J Psychiatr Pract"},{"issue":"2","key":"2020060307362733700_i2168-9709-10-1-18-b05","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2020060307362733700_i2168-9709-10-1-18-b06","article-title":"Member profile [Internet]","year":"2019"},{"issue":"6","key":"2020060307362733700_i2168-9709-10-1-18-b07","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/2045125315612013","article-title":"Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey","volume":"5","author":"Emsley","year":"2015","journal-title":"Ther Adv In"},{"key":"2020060307362733700_i2168-9709-10-1-18-b08","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/PPA.S37534","article-title":"Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa","volume":"7","author":"Olivares","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"2020060307362733700_i2168-9709-10-1-18-b09","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004408.pub5","article-title":"Compulsory community and involuntary outpatient treatment for people with severe mental disorders","volume":"3","author":"Kisely","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2020060307362733700_i2168-9709-10-1-18-b10","doi-asserted-by":"publisher","first-page":"e1000074","DOI":"10.1371\/journal.pmed.1000074","article-title":"No more free drug samples?","volume":"6","author":"Chimonas","year":"2009","journal-title":"PLoS Med"},{"issue":"7","key":"2020060307362733700_i2168-9709-10-1-18-b11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.9740\/mhc.n90206","article-title":"Drug-induced movement disorders","volume":"1","author":"Chen","year":"2012","journal-title":"Ment Health Clin [Internet]"},{"issue":"4","key":"2020060307362733700_i2168-9709-10-1-18-b12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.9740\/mhc.2016.07.178","article-title":"Atypical antipsychotics: a review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects","volume":"6","author":"Wei Xin Chong","year":"2016","journal-title":"Ment Health Clin [Internet]"},{"issue":"1","key":"2020060307362733700_i2168-9709-10-1-18-b13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/BF02790478","article-title":"The ethical challenges of a randomized controlled trial of involuntary outpatient commitment","volume":"24","author":"Swartz","year":"1997","journal-title":"J Ment Health Adm"},{"issue":"7","key":"2020060307362733700_i2168-9709-10-1-18-b14","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.5688\/ajpe8175925","article-title":"Curriculum in psychiatry and neurology for pharmacy programs","volume":"81","author":"Dopheide","year":"2017","journal-title":"Am J Pharm Educ"},{"issue":"2","key":"2020060307362733700_i2168-9709-10-1-18-b15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5688\/aj720243","article-title":"Response rates and responsiveness for surveys, standards, and the Journal","volume":"72","author":"Fincham","year":"2008","journal-title":"Am J Pharm Educ"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/10\/1\/18\/2427621\/mhc_2020_01_018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/10\/1\/18\/2427621\/mhc_2020_01_018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:18:54Z","timestamp":1731687534000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/10\/1\/article-p18.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2020.01.018","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]}}}